249 related articles for article (PubMed ID: 12807239)
1. p53 overexpression as a prognostic indicator in endometrial carcinoma.
Ozalp S; Yalcin OT; Tanir HM; Kabukcuoglu S; Erol G
Eur J Gynaecol Oncol; 2003; 24(3-4):275-8. PubMed ID: 12807239
[TBL] [Abstract][Full Text] [Related]
2. Microvessel density (MVD) as a prognosticator in endometrial carcinoma.
Ozalp S; Yalcin OT; Acikalin M; Tanir HM; Oner U; Akkoyunlu A
Eur J Gynaecol Oncol; 2003; 24(3-4):305-8. PubMed ID: 12807245
[TBL] [Abstract][Full Text] [Related]
3. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma.
Osmanağaoğlu MA; Kadioğlu S; Osmanağaoğlu S; Bozkaya H; Reis A; Tekelioğlu Y
Eur J Gynaecol Oncol; 2005; 26(1):64-70. PubMed ID: 15755004
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma.
Ohkouchi T; Sakuragi N; Watari H; Nomura E; Todo Y; Yamada H; Fujimoto S
Am J Obstet Gynecol; 2002 Aug; 187(2):353-9. PubMed ID: 12193924
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
7. Parametrial spread is a prognostic factor in endometrial carcinoma.
Sato R; Jobo T; Kuramoto H
Eur J Gynaecol Oncol; 2003; 24(3-4):241-5. PubMed ID: 12807232
[TBL] [Abstract][Full Text] [Related]
8. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer.
Geisler JP; Geisler HE; Wiemann MC; Zhou Z; Miller GA; Crabtree W
Gynecol Oncol; 1999 Sep; 74(3):468-71. PubMed ID: 10479512
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
10. p53 protein overexpression in early stage endometrial cancer.
Kohlberger P; Gitsch G; Loesch A; Tempfer C; Kaider A; Reinthaller A; Kainz C; Breitenecker G
Gynecol Oncol; 1996 Aug; 62(2):213-7. PubMed ID: 8751552
[TBL] [Abstract][Full Text] [Related]
11. p53 staining as a prognostic indicator in endometrial carcinoma.
Ozsaran AA; Türker S; Dikmen Y; Erhan Y; Itil I; Terek C; Ozdemir N
Eur J Gynaecol Oncol; 1999; 20(2):156-9. PubMed ID: 10376438
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular space involvement is the sole independent predictor of lymph node metastasis in clinical early stage endometrial cancer.
Vaizoglu F; Yuce K; Salman MC; Basaran D; Calis P; Ozgul N; Usubutun A
Arch Gynecol Obstet; 2013 Dec; 288(6):1391-7. PubMed ID: 23764931
[TBL] [Abstract][Full Text] [Related]
13. [Clinical implications of positive peritoneal cytology in endometrial cancer].
Ren YL; Wang HY; Shan BE; Ping B; Shi DR
Zhonghua Fu Chan Ke Za Zhi; 2011 Aug; 46(8):595-9. PubMed ID: 22169518
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in surgical stage I endometrial carcinoma.
Lundgren C; Auer G; Frankendal B; Nilsson B; Nordström B
Acta Oncol; 2004; 43(1):49-56. PubMed ID: 15068320
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53 in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
[TBL] [Abstract][Full Text] [Related]
16. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
17. Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement.
Wong FC; Pang CP; Tang SK; Tung SY; Leung TW; Sze WK; Cheung KB
Clin Oncol (R Coll Radiol); 2004 Aug; 16(5):350-5. PubMed ID: 15341439
[TBL] [Abstract][Full Text] [Related]
18. Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma.
Stewart KD; Martinez AA; Weiner S; Podratz K; Stromberg JS; Schray M; Mitchell C; Sherman A; Chen P; Brabbins DA
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):527-35. PubMed ID: 12243832
[TBL] [Abstract][Full Text] [Related]
19. The value of ultrasonography in preoperative assessment of selected prognostic factors in endometrial cancer.
Sawicki W; Spiewankiewicz B; Stelmachów J; Cendrowski K
Eur J Gynaecol Oncol; 2003; 24(3-4):293-8. PubMed ID: 12807243
[TBL] [Abstract][Full Text] [Related]
20. Endometrioid adenocarcinoma of the uterus: surgico-pathological correlations and role of pelvic lymphadenectomy.
Chee JJ; Ho TH; Tay EH; Low JJ; Yam KL
Ann Acad Med Singap; 2003 Sep; 32(5):670-5. PubMed ID: 14626800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
